兆科眼科-B(06622):国家药监局受理用于治疗儿童近视加深的NVK002(硫酸阿托品滴眼液0.02%)的新药上市申请

智通财经
09 Jul

智通财经APP讯,兆科眼科-B(06622)公布,中国国家药品监督管理局最近受理该公司核心产品之一、用于治疗儿童近视加深的NVK002(硫酸阿托品滴眼液0.02%)的新药上市申请。该新药申请分类为II类创新药。

公司早前于2025年1月2日宣布,中国国家药监局已受理用于治疗儿童近视加深的NVK002(硫酸阿托品滴眼液0.01%)的简化新药申请。该药物现正处于审评过程中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10